CERAVOLO, ROBERTO
 Distribuzione geografica
Continente #
NA - Nord America 15.751
EU - Europa 6.982
AS - Asia 1.930
AF - Africa 308
SA - Sud America 19
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 11
Totale 25.018
Nazione #
US - Stati Uniti d'America 15.367
IT - Italia 2.759
SE - Svezia 1.383
CN - Cina 1.067
BG - Bulgaria 768
DE - Germania 562
CA - Canada 380
GB - Regno Unito 330
AT - Austria 309
VN - Vietnam 285
UA - Ucraina 259
FI - Finlandia 213
TR - Turchia 199
CI - Costa d'Avorio 190
SG - Singapore 179
CH - Svizzera 116
RU - Federazione Russa 101
HK - Hong Kong 93
SN - Senegal 70
IN - India 62
FR - Francia 56
NG - Nigeria 46
PL - Polonia 34
BE - Belgio 29
NL - Olanda 17
AU - Australia 14
ES - Italia 13
KR - Corea 13
IE - Irlanda 12
EU - Europa 11
JP - Giappone 9
IR - Iran 8
BR - Brasile 7
AR - Argentina 5
CO - Colombia 5
EE - Estonia 4
GR - Grecia 4
IL - Israele 4
TW - Taiwan 4
MX - Messico 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
HR - Croazia 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BD - Bangladesh 1
CL - Cile 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EG - Egitto 1
LU - Lussemburgo 1
MY - Malesia 1
PH - Filippine 1
SA - Arabia Saudita 1
SI - Slovenia 1
ZA - Sudafrica 1
Totale 25.018
Città #
Woodbridge 1.951
Fairfield 1.863
Ann Arbor 1.346
Houston 1.326
Chandler 1.273
Ashburn 1.037
Milan 838
Seattle 801
Sofia 768
Wilmington 693
Cambridge 583
Serra 523
New York 509
Jacksonville 394
Princeton 383
Beijing 368
Ottawa 362
Lawrence 303
Vienna 290
Medford 279
Izmir 192
Abidjan 190
Nanjing 188
Des Moines 179
Pisa 160
Dearborn 154
Florence 150
Frankfurt am Main 146
Bern 113
Dong Ket 112
San Diego 99
Hong Kong 85
Rome 85
London 80
Nanchang 79
Bremen 75
Dakar 70
Jüchen 67
Redwood City 65
Norwalk 59
Ogden 59
Lancaster 58
Los Angeles 50
Shenyang 50
Kunming 48
Lagos 46
Hebei 44
Pune 35
Guangzhou 34
Warsaw 32
Changsha 31
Brussels 29
Vicopisano 29
Hefei 26
Trieste 26
Tianjin 25
Jiaxing 24
Boulder 22
Falls Church 22
Washington 19
Lucca 18
San Francisco 17
Hangzhou 16
Nürnberg 16
Boardman 15
Auburn Hills 14
Chicago 13
Jinan 11
Kent 11
La Spezia 11
Livorno 11
Phoenix 11
Düsseldorf 10
Costa Mesa 9
Detroit 9
Shanghai 9
Verona 9
Viareggio 9
Council Bluffs 8
Haikou 8
Massa E Cozzile 8
Medolago 8
Changchun 7
Helsinki 7
Indiana 7
Messina 7
Orange 7
San Giuliano Terme 7
Central District 6
Dallas 6
Edinburgh 6
Kilburn 6
Kostroma 6
Paris 6
Tappahannock 6
Torino 6
Capannori 5
Lanzhou 5
Madrid 5
Zhengzhou 5
Totale 19.308
Nome #
Cataract surgery under topical anesthesia in a patient with Parkinson disease and deep brain stimulation: a report of feasibility. 247
Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study 241
Vascular Function Is Improved After an Environmental Enrichment Program: The Train the Brain-Mind the Vessel Study 172
Disfunzioni sessuali nel morbo di Parkinson: review 162
A case of pelvic floor myoclonic jerk syndrome. 159
The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects 157
Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study 147
Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease 147
Acute and chronic effects of clozapine in essential tremor 146
Leadless cardiac pacemaker implant in a patient with two deep brain stimulators: a peaceful cohabitation beyond prejudices 146
CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease 144
α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity 144
Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease 141
Mitochondrial DNA single deletion in a patient with postural tremor. 141
Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease. 140
Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction 139
Evolution of clinical features in possible DLB depending on FP-CIT SPECT result 138
Lack of association between mtDNA haplogroups and Alzheimer's disease in Tuscany 138
Mesolimbic dopaminergic dysfunction in Parkinson's disease depression: evidence from a 123I-FP-CIT SPECT investigation. 136
The precuneus-a witness for excessive aβ gathering in alzheimer's disease pathology 136
The hOGG1 Ser326Cys polymorphism and Huntington's disease 134
A pilot psychometric study of aberrant salience state in patients with Parkinson's disease and its association with dopamine replacement therapy. 134
Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders 133
Serotonin and neurodegeneration: a preliminary study of platelet serotonin transporter (SERT) in patients with Huntington's disease 133
Social Cognition and Oxytocin in Huntington’s Disease: New Insights 130
Caudate dopaminergic denervation and visual hallucinations: Evidence from a 123I-FP-CIT SPECT study 127
SSRIs do not worsen Parkinson's disease: Evidence from an open-label, prospective study 126
Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes 126
[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism 126
A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting 126
null 125
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study 124
Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. 123
Psychosis associated to Parkinson's disease in the early stages: Relevance of cognitive decline and depression 123
Aerobic rehabilitation program for improving muscle function in Parkinson's disease 122
Iowa Gambling Task in de novo Parkinson's disease: a comparison between good and poor performers 121
Event-based prospective memory in newly diagnosed, drug-naive Parkinson's disease patients 121
Efficacy of a combined therapeutic approach in the management of Pisa Syndrome 120
Decision making in de novo Parkinson's disease 119
The association between motor subtypes and alexithymia in de novo Parkinson's disease. 118
Non-motor symptoms in atypical and secondary parkinsonism: The PRIAMO study 117
Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers 117
Myopathic involvement in two cases of Hallervorden-Spatz disease 116
Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology. 116
Depressive symptoms in Parkinson's disease 115
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. 114
Current treatment and future prospects of dopa-induced dyskinesias. 114
The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-na?ve patients with Parkinson's disease. 113
Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders 113
Antipsychotic drugs in Huntington's disease 113
The mtDNA A8344G "MERRF" mutation is not a common cause of sporadic Parkinson disease in Italian population 112
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease 112
Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients 111
No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease 110
Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy 109
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire 109
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. 108
Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder 108
Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. 108
Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. 108
null 108
Association between amantadine and the onset of dementia in Parkinson's disease 107
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in Parkinsonian patients 107
Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging 107
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease 106
Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines. 105
Role of pramipexole in the management of Parkinsons disease 105
Unilateral periodic limb movements: is this a pointer for atypical presentation of corticobasal degeneration syndrome?--A case report 104
Nonmotor symptoms in Parkinson’s disease: the dark side of the moon 104
Molecular imaging to track Parkinson's disease and atypical parkinsonisms: new imaging frontiers 104
Morphometric and functional MRI changes in essential tremor with and without resting tremore. 104
Psychiatric comorbidity in a population of Parkinson's disease patients 103
Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items". 103
Apomorphine hydrochloride for the treatment of Parkinson's disease. 103
null 103
A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. 102
Reliability of administrative data for the identification of Parkinson's disease cohorts. 102
Advances in the pharmacotherapeutic management of dementia with Lewy bodies 102
Antioxidants in the Diet and Cognitive Function: Which Role for the Mediterranean Life-style? 101
Effects of combined training on neuropsychiatric symptoms and quality of life in patients with cognitive decline 101
Alexithymia is associated with depression in de novo Parkinson's disease 100
Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease. 100
The Italian Dystonia Registry: rationale, design and preliminary findings 100
Sindrome da encefalopatia posteriore reversibile (PRES) in una paziente psoriasica in trattamento con ciclosporina 99
Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma 99
Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition 99
Oxidative stress assessment in Alzheimer's disease: a clinic setting study 99
Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports 98
A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. 98
Correlation between vestibular abnormalities and MRI findings in cerebellar ataxia 97
Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease 97
Evaluating the SERCA2 and VEGF mRNAs as potential molecular biomarkers of the onset and progression in huntington's disease 97
Expanding the clinical phenotype of DYT5 mutations: is multiple system atrophy a possible one? 96
Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia 95
18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease 95
Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. 95
Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study 95
Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study 94
Correction to: The Italian Dystonia Registry: rationale, design and preliminary findings (Neurological Sciences, (2017), 38, 5, (819-825), 10.1007/s10072-017-2839-3) 94
Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases 94
Totale 11.897
Categoria #
all - tutte 67.300
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.300


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.164 0 0 0 0 0 0 0 0 0 0 657 507
2019/20204.909 579 343 448 292 434 568 596 423 520 261 351 94
2020/20212.335 175 164 151 96 197 146 287 186 240 174 136 383
2021/20223.334 44 125 71 254 657 440 93 177 199 99 226 949
2022/20234.379 570 545 347 359 473 550 39 316 784 23 292 81
2023/20243.526 459 421 418 326 574 773 147 136 32 73 167 0
Totale 25.548